The potential benefits of ribavirin and pleconaril treatment on type 1 diabetes

Researchers investigate whether ribavirin and pleconaril could stimulate endogenous insulin production among individuals with incident type 1 diabetes.

Trade group tells FDA that semaglutide is not too ‘complex’ for compounding

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 5, 2024

Lilly’s EBGLYSS gains approval for patients 12 years and older

EBGLYSS can be administered with or without topical corticosteroids. Credit: Eli Lilly and Company. Eli Lilly and Company has announced FDA approval of EBGLYSS (lebrikizumab-lbkz)

September 16, 2024

Vertex shares up after full-year product revenue guidance boost – Pharmaceutical Technology

Shares in Vertex rose following the lifted guidance for 2024. Image credit: Shutterstock / JHVEPhoto. Vertex Pharmaceuticals has seen a 12% revenue uptick in Q3

November 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.